Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Safety Issues, Tolerance
- Main trialPhase 1
- “Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.”In the company’s words, NCT05105243 on ClinicalTrials.gov
Other drugs for Tolerance
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- Efimosfermin AlfaGSK · Phase 3
- PegozaferminHoffmann-La Roche · 89bio, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- SemaglutideNovo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 30 Oct 2022 | Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026